FUJIFILM Holdings Corp.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From FUJIFILM Holdings Corp.
As the clock ticks down to the US election day on 3 November, President Trump maintains that the first COVID-19 vaccine emergency use approval is imminent. Meanwhile, Fujifilm Toyama's Avigan is near to Japanese approval.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.
Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.
- Other Names / Subsidiaries
- FujiFilm Diosynth Biotechnologies USA, Inc. (FDBU)
- Fuji Xerox Co. Ltd.
- Kalon Biotherapeutics LLC
- SonoSite, Inc.
- Toyama Chemical Co. Ltd.
- Salmon Acquisition Corporation
- FUJIFILM Toyama Chemical Co., Ltd
- FUJIFILM RI Pharma Co., Ltd
- Irvine Scientific Sales Company, Inc.
- IS Japan Co. Ltd.
- FUJIFILM Group
- Cellular Dynamics International, Inc.
- Opsis Therapeutics
- Shenandoah Biotechnology, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.